BioNano Genomics Inc (NASDAQ:BNGO) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $11.50 for the company and are predicting that the company will post ($0.57) earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioNano Genomics an industry rank of 64 out of 256 based on the ratings given to related companies.
A number of research firms recently issued reports on BNGO. Maxim Group reissued a “buy” rating and issued a $12.00 price target on shares of Intec Pharma in a research note on Thursday, June 20th. Zacks Investment Research raised shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research note on Monday, July 8th.
Shares of NASDAQ:BNGO traded up $0.07 during midday trading on Thursday, hitting $2.60. 188 shares of the stock traded hands, compared to its average volume of 16,368. The stock has a market cap of $27.44 million and a PE ratio of -1.00. The stock’s 50 day simple moving average is $2.68. The company has a debt-to-equity ratio of 3.13, a current ratio of 5.94 and a quick ratio of 5.64. BioNano Genomics has a one year low of $2.35 and a one year high of $10.00.
BioNano Genomics (NASDAQ:BNGO) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.12). The firm had revenue of $1.85 million for the quarter, compared to analysts’ expectations of $1.76 million. Sell-side analysts expect that BioNano Genomics will post -2.25 earnings per share for the current year.
BioNano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Read More: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.